There are 116 resources available
Audience Q&A: Expert Insights on Your Inquiries in nmCRPC
Presenter: Elena Castro, Fred Saad, Martin Boegemann
Session: PeerVoice - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
Resources:
Webcast
Optimizing the approach to MRD assay development
Presenter: Rick Baehner
Session: Exact Sciences - Tools to guide treatment decisions in early breast cancer: Genomic testing and emerging role of MRD
Resources:
Webcast
Final Remarks, Conclusions, and Closing
Presenter: Elena Castro
Session: PeerVoice - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
Resources:
Webcast
Panel discussion
Presenter: Nicholas Turner, Miguel Martin Jimenez, Sherene Loi, Janice Walshe, Rick Baehner
Session: Exact Sciences - Tools to guide treatment decisions in early breast cancer: Genomic testing and emerging role of MRD
Resources:
Webcast
Meeting Close
Presenter: Christine Parseghian
Session: Merck Healthcare KGaA - Shaping the Future: Breakthroughs and challenges in mCRC
Resources:
Webcast
Welcome
Presenter: Carlos Barrios
Session: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
Resources:
Webcast
Welcome and Introduction
Presenter: Kim Nguyen Chi
Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?
Resources:
Webcast
PI3K: Unmet need has driven a succession of targeting attempts
Presenter: Kevin Kalinsky
Session: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
Resources:
Webcast
Where do we stand? Current recommendations for radioligand therapy (RLT) in metastatic castration-resistant prostate cancer
Presenter: Kim Nguyen Chi, Matthias Eiber, Joan Carles Galceran, Jochen Walz
Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?
Resources:
Webcast
PI3Ki: Continued efforts are showing success
Presenter: Komal Jhaveri
Session: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
Resources:
Webcast